Catalog Advanced Search

Search by Categories
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By
  • 2021 Webinar: Natural History of NAFLD/NASH in Children: Knowledge, Gaps and Interventions

    Contains 2 Component(s) Recorded On: 06/02/2021

    Webinar hosted by the Pediatric Liver Disorders Special Interest Group on June 2, 2021.

    The gap in natural history data for NAFLD/NASH in children is large, but there have been some significant advances made in the past couple of years. This webinar aims to increase awareness, enhance knowledge and improve health of children with this disorder.

    Shikha Sundaram

    Shikha S. Sundaram, MD, FAASLD, is an associate professor of Pediatrics at Children’s Hospital Colorado and the University of Colorado School of Medicine. As a pediatric hepatologist and translational researcher with expertise in pediatric NAFLD, she studies the impact of chronic intermittent hypoxia on disease progression.

    Dr. Sundaram is a member of the AASLD NASH Task Force and the Annual Meeting Education Committee. She has published extensively in pediatric NAFLD, but also on the impact of undernutrition on pediatric liver disease as well as long term outcomes in pediatric liver disease and transplantation. She serves on the board of the National Charity League and on the Medical Advisory Committee for the Rocky Mountain American Liver Foundation and Round Up River Ranch.

    Samar Ibrahim (Moderator)

    Samar Ibrahim, M.B.Ch.B is an associate professor of Pediatrics and Physiology at the Division of Pediatric Gastroenterology and Hepatology in Mayo Clinic. Dr. Ibrahim is a pediatric  transplant hepatologist  and a physician scientist. Her research focus is to study the mechanism of liver injury and inflammation in nonalcoholic steatohepatis (NASH), with  the goal to identify novel biomarkers and mechanism-based therapeutic targets. Her recently published work identified the vascular adhesion molecule 1 (VCAM1) as a potential novel therapeutic target in NASH. Dr. Ibrahim and her research team have examined the role of extracellular vesicles as biomarkers, as well as mediators of intercellular communication in NASH pathobiology. They recently defined the role of integrin beta1-enriched extracellular vesicles in NASH. Dr. Ibrahim serves as the medical director of the pediatric liver transplant program at Mayo clinic, and is interested in studying factors responsible for late liver graft dysfunction, as well as developing models that better predict the acuity of the pediatric liver transplant candidate on the wait list.

    Dr. Ibrahim is a member of the editorial board for HEPATOLOGY and the American Journal of Physiology, gastrointestinal and liver physiology. She is currently and active member of the hepatology committee at the North American Society of Pediatric Gastroenterology Hepatology and Nutrition (NASPGHAN) and the education committee and the advocacy committee at the study of pediatric liver transplant (SPLIT).  Dr. Ibrahim serves on the steering committee for the pediatric SIG at AASLD. Dr. Ibrahim is the Principal Investigator of the lipotoxicity and liver inflammation laboratory at Mayo Clinic.  She is an active member of the center of cell signaling in gastroenterology at Mayo Clinic and moderates the center weekly scientific seminar series. Dr. Ibrahim has served on  NIDDK study sections, as well as a reviewer for international funding agencies. Dr. Ibrahim  has mentored numerous medical students, residents, and postdoctoral fellows.

    Rohit Kohli (Moderator)

    Rohit Kohli, MBBS, MS, FASSLD is the chief of the division of Gastroenterology, Hepatology and Nutrition, and associates chair in Liver and Intestinal Research, at the Children’s Hospital Los Angeles. He is also a Professor of Pediatrics (Clinical Scholar) at the Keck School of Medicine at the University of Southern California. His clinical training and 20 years of experience have focused on caring for children needing liver transplant. Currently his administrative responsibility includes the highest ranked program for Pediatric Gastroenterology on the West Coast of the United States. His clinical, translational and basic science research work has been focused on obesity-related fatty liver disease (NASH) and weight loss surgery with 15 plus years of continuous funding support from the National Institutes of Health.

    Dr. Kohli has served as editorial/advisory board member for major journals such as HEPATOLOGY, Pediatric Transplantation and Pediatric Obesity. He is currently Vice-Chair of the Pediatric Hepatology Special Interest Group for the American Association for the Study of Liver Diseases (AASLD) and a member of the nominating committee of the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). He is an active teacher and educator, with the current added responsibility of being the director of the Pediatric Scientists Program (Donnell Scholar Program) at Children’s Hospital Los Angeles. 

  • 2021 Webinar: Challenges in NASH Clinical Trials

    Contains 2 Component(s) Recorded On: 05/19/2021

    Webinar hosted by the Nonalcoholic Fatty Liver Disease Special Interest Group on May 19, 2021.

    Join the Nonalcoholic Fatty Liver Disease Special Interest Group in discussing the current challenges in histological assessment in NASH clinical trials. Presenters will also discuss how to implement hard outcomes in NASH clinical trials and the use non-invasive biomarkers as primary endpoints for drug approval.

    Naim Alkhouri

    Naim Alkhouri, MD is the VP of Academic Affairs, Chief of Transplant Hepatology, and Director of the Fatty Liver Program at Arizona Liver Health (ALH) in Phoenix, AZ.

    Prior to joining ALH, Dr. Alkhouri served as the director of the Metabolic Health Center at the Texas Liver Institute and Associate Professor of Medicine and Pediatric at the University of Texas (UT) Health in San Antonio, TX.

    Dr. Alkhouri completed his Gastroenterology and Transplant Hepatology training at the renowned Cleveland Clinic in Cleveland, OH where he was also appointed Assistant Professor of Medicine and Director of the Metabolic Liver Disease Clinic at the Cleveland Clinic Digestive Disease and Surgery Institute.

    Dr. Alkhouri is a key opinion leader in the field of NASH therapeutics and an advisor/ consultant to many pharmaceutical and biomarker development companies.  He is Principal Investigator on several multicenter global NASH trials and a member of the AASLD NASH Special Interest Group (NASH SIG). Among many research awards, Dr. Alkhouri received the American College of Gastroenterology Junior Faculty Development Award to study the analysis of breath volatile organic compounds to diagnose nonalcoholic fatty liver disease. Dr. Alkhouri's specialty interests include nonalcoholic fatty liver disease, metabolic liver diseases, viral hepatitis, autoimmune hepatitis, alpha 1 antitrypsin deficiency, and liver transplantation. Dr. Alkhouri has been published in over 200 publications and presents his work at both national and international medical conferences.

    Manal F. Abdelmalek

    Manal F.Abdelmalek, MD, MPH, FAASLD is a tenured Professor of Medicine in the Divisionof Gastroenterology and Hepatology and Director of the Nonalcoholic Fatty LiverDisease (NAFLD) Clinical Research Program at Duke University. Since firstreporting on nonalcoholic steatohepatitis (NASH) as a cause of cryptogeniccirrhosis nearly 25 years ago, her clinical and research area of interest hasfocused on NAFLD / NASH, associated risk factors for disease acquisition andprogression and the discovery of novel approaches to treatment.   She has expertise in clinical-translationalresearch, the design and conduct of clinical trials, includinginvestigator-initiated, industry sponsored and NIH-funded clinical studies evaluatingnew therapies and biomarkers for NAFLD and NASH.  She collaborates extensively to translate newcompounds to first-in-man clinical studies and translate clinic-to-bench andbench-to-clinic research to define pathogenic mechanisms underlying NAFLD acquisitionand progression and new compounds into first-in-man clinical studies.  She is the lead Principal Investigator onseveral multicenter global studies, a member of the AASLD Global Outreach andEngagement Committee and past member of the AASLD Clinical Research Committee. Dr.Abdelmalek is a Fellow of American College of Physicians, American College ofGastroenterology and American Association for the Study of Liver Disease.  She is a standing member of NASH ClinicalResearch Network (NASH CRN) for the past 15 years, has published more than 200manuscripts and currently serves on the Editorial Board of HEPATOLOGY, theofficial journal of the AASLD.  

    Mazen Noureddin

    Mazen Noureddin, MD, MHSc is the founding director of the Fatty Liver Program at Cedars-Sinai Medical Center. His focus is on clinical and translational research in the area of NAFLD/NASH. Dr. Noureddin has conducted more than 35 investigational clinical studies of novel treatments for NASH. In addition, he has an interest in non-invasive testing and biomarkers of the field, especially metabolomics, serum biomarkers, trainset elastography, and magnetic resonance imaging techniques. Dr. Noureddin has published in all these areas. He has given invited lectures on NAFLD/NASH at national and international society meetings and serves on several steering committees/advisory boards for industry. He is the chair of the AASLD NASH special interest group education sub-committee and serves on the editorial board for the journals “Clinical Gastroenterology and Hepatology (CGH)” and “Gastroenterology”. He is also member of the incoming board of editors (2022) for Clinical Gastroenterology and Hepatology (CGH). He is funded by the National Cancer Institute. 

    Vlad Ratziu (Moderator)

    Vlad Ratziu, MD, PhD is a professor of hepatology at Sorbonne University, and performs his hospital work at the Pitié-Salpêtrière Hospital and the Institute for Cardiometabolism and Nutrition (ICAN) in Paris, France. Professor Ratziu received his medical training at Paris Descartes University; he then completed a two-year postdoctoral fellowship at the Liver Center at the University of California, San Francisco, CA, USA, and went on to earn a doctoral degree from Paris Diderot University for his work on the pathophysiology of viral and metabolic liver fibrosis.

    Professor Ratziu’s main research interests are in the field of non-alcoholic fatty liver disease (NAFLD); the mechanisms, risk factors, and progression of liver fibrosis in viral and metabolic diseases; and the treatment of viral hepatitis and hepatocellular carcinoma. He coordinated or participated in several therapeutic trials in NASH. He was also involved in different European financed FP7, Horizon 2020 and Innovative Medicines Initiative 2 consortia. He is a member of the organising committee of the NASH–TAG meetings. He is a co-editor for the Journal of Hepatology and an associate editor for Clinical Liver Disease. He has published more than 300 articles in top-tier specialty journals.

  • 2021 Webinar: FY21 Peer Reviewed Cancer Research Program Funding Opportunities in Liver Cancer

    Product not yet rated Contains 2 Component(s) Recorded On: 04/12/2021

    Webinar hosted by the Public Policy Committee on April 12, 2021.

    The Peer Reviewed Cancer Research Program webinar will present funding opportunities for liver cancer through the Department of Defense. This webinar will cover topics including how to apply, what opportunities are available, as well as hints and tips on how to succeed in applying to the Department of Defense Congressionally Directed Medical Research Programs.

    Donna M. Kimbark

    Donna M. Kimbark, PhD currently serves as the Program Manager at the Congressionally Directed Medical Research Programs, U.S. Army Medical Research and Development Command.

    In 1996, Dr. Kimbark received her PhD in Molecular Pharmacology and Cancer Therapeutics from the State University of New York at Buffalo, Roswell Park Cancer Institute. Following postdoctoral training at Johns Hopkins Medical Institute, Dr. Kimbark worked in the biotechnology sector before joining the Congressionally Directed Medical Research Programs (CDMRP) in 2002 as Science Officer for the Breast Cancer Research Program. During her time as a Science Officer, Dr. Kimbark also served on the Institution Based Research Program group and served as Chair of the Consumer Working Group. While working in grants management, she received her certificate in Epidemiology and Biostatistics from Drexel University. In 2008, Dr. Kimbark was promoted to Program Manager for the Peer Reviewed Cancer Research Program.  Throughout her years at CDMRP, Dr. Kimbark has led multiple research funding programs including Autism, Multiple Sclerosis, Kidney Cancer, and Bone Marrow Failure Research Programs. Currently, she leads the program teams for the Peer Reviewed Cancer Research Program and the Melanoma Research Program.  In addition to her programmatic duties, Dr. Kimbark also leads the Funding Opportunities Announcement team, where she coordinates the creation and revisions solicitation templates for grants. For her efforts, she has been awarded the Commander’s Award for Civilian Service. Her areas of expertise include cancer therapeutics, pharmacology, proteomics, and scientific research administration.

  • 2021 Webinar: Simultaneous Liver Kidney Transplant: How Did We Do With the New Criteria?

    Product not yet rated Contains 2 Component(s) Recorded On: 03/29/2021

    Webinar hosted by the Liver Transplantation and Surgery Special Interest Group on March 29, 2021.

    In this one hour on-demand webinar, we will discuss how we arrived at the new organ allocation schema for simultaneous liver kidney (SLK) transplants by UNOS in partnership with our Transplant Nephrologists and the effect this has had on dual organ allocation and outcomes of SLK transplantation.

    Ryutaro Hirose

    Ryutaro Hirose, MD is professor and vice chair of clinical operations and value for the Department of Surgery at the University of California, San Francisco. He is an active liver, kidney and pancreas transplant surgeon. He currently serves as the Surgical Director of the Scientific Registry of Transplant Recipients (SRTR). He is a Councilor-at-large for the American Society of Transplant Surgeons (ASTS).

    Dr. Hirose has served as the chair of the ASTS Fellowship Training Committee and the ASTS Standards and Quality Committee. He spearheaded the creation and development of a National Transplant Quality Program with the ASTS and the American College of Surgeons. He has served as vice chair and chair of the UNOS Liver and Intestinal Organ Transplantation committee and led the development and implementation of the new liver distribution system, the national liver review board, HCC and MELD exception policy and the Simultaneous Liver Kidney Transplant (SLK). He has served on the board of directors and chair of the medical advisory board of donor network west, the local organ procurement agency for Northern California. Dr. Hirose has served as an associate editor for Clinical Transplantation. He has also served as the associate program director of the UCSF Surgical Residency program for over 15 years. His academic and scholarly interests include ischemia-reperfusion injury, hepatocellular carcinoma, transplant outcomes and organ allocation and distribution policy, with over 120 peer-reviewed articles in these specific areas. As an active educator and advisor, he has mentored over 100 surgical residents, medical students, fellows and junior faculty, both at UCSF and other institutions.

    Richard Formica

    Richard N. Formica Jr., MD is a professor of medicine and surgery, director of transplant medicine and the medical director of the Kidney Transplant Program at Yale University School of Medicine. Dr. Formica is a practicing transplant nephrologist. He is currently the President of the American Society of Transplantation and the OPTN/UNOS Regional 1 Associate Counselor and the Region 1 Representative to the OPTN/UNOS Membership and Professional Standards Committee.

    Dr. Formica has extensive expertise in public policy as it pertains to the solid organ transplantation. He been an active participant in the United Network of Organ Sharing since 2009. During this involvement he held leadership positions as the Chairman of the Kidney Paired Donation Work Group, the Kidney Transplantation Committee and the Simultaneous Liver-Kidney Transplantation Working Group. In these roles, he participated in the design, public vetting and implementation of public policy regarding, living kidney donation, deceased donor kidney allocation and the medically appropriated and fair allocation of deceased donor kidneys with deceased donor livers. Dr. Formica has been involved with the Clinical Trials in Organ Transplantation since inception, having been a site PI on CTOT-1, CTOT-9, CTOT -17 and currently is the site PI for CTOT -19. Dr. Formica has authored or co-authored 79 peer reviewed manuscripts and numerous book chapters. He is currently the Associate Editor for the Clinical Journal of the American Society of Nephrology responsible for the transplant portfolio.

    David Mulligan (Moderator)

    David C. Mulligan, MD, FACS, FAST, FAASLD is an abdominal organ transplant surgeon performing both living and deceased donor liver, kidney and pancreas transplants. He currently serves as Professor and Chair of Transplantation and Immunology in the Department of Surgery at Yale University School of Medicine/Yale New Haven Health System. His clinical and academic focus surrounds living donor liver transplantation, expanding donation, and working on ways to utilize ex-vivo organ perfusion systems to increase transplantation in the U.S.

    Dr. Mulligan’s leadership in solid organ transplantation across national and international platforms has grown considerably and he now serves as the President of the United Network of Organ Sharing (UNOS)/Organ Procurement Transplant Network (OPTN), Member At-Large on the Governing Board of the American Association for the Study of Liver Diseases, Chair of the Advisory Council on Transplantation (ACOT) to the Secretary of HHS, Special Government Employee for FDA Medical Device Advisory Committee and Chair of the Business Practice Committee of the American Society of Transplant Surgeons. In these visionary roles, he has led major changes in organ allocation and distribution and will hopefully culminate in substantial increases in organ transplants. Passionate about patient-centered care and building more resilient teams, he makes time to share his enjoyment of spending time in nature, especially near the ocean, with his wife and three children.

    Michael L. Schilsky (Moderator)

    Michael L. Schilsky, MD, FAASLD completed his medical education at the University of Chicago, Pritzker School of Medicine and then trained in internal medicine and gastroenterology at The Albert Einstein College of Medicine. After a post-doctoral training fellowship at the Liver Research Center of the Albert Einstein College of Medicine he joined the faculty there and rose to the rank of Associate Professor.

    Dr. Schilsky moved to The Mount Sinai School of Medicine in 1989 to begin his work in the field of liver transplantation and was recruited in 2003 to the Weill Cornell Medical Center where he partnered with the transplant program at Columbia Presbyterian. Dr. Schilsky was again recruited in 2007 to Yale as Medical Director for the Liver Transplant program and rose to the rank of Professor of Medicine and Surgery. He also is a member of the NIH sponsored Acute Liver Failure Study Group and chairs their publications committee. He is a former UNOS Region 1 representative for the Liver and Intestine Committee and is the current Chair of the Special Interest Group for Liver Transplantation and Surgery sponsored by the American Association for the Study of Liver Disease (AASLD).

  • 2021 Emerging Topic Conference: Chronic Hepatitis B: From Population to New Molecules and Back

    Contains 10 Component(s), Includes Credits

    This conference will provide a comprehensive and in-depth discussion of the most updated treatment strategies as well as data/care gap to prevent and manage the HBV population. A review of the preclinical and clinical frontiers of HBV cure molecules after a state-of-the-art review of novel molecular and immunologic HBV cure markers will be covered along with an assessment of HBV cure’s impact on HBV epidemiology and population health.

    This conference will provide a comprehensive and in-depth discussion of the most updated treatment strategies as well as data/care gap to prevent and manage the HBV population. A review of the preclinical and clinical frontiers of HBV cure molecules after a state-of-the-art review of novel molecular and immunologic HBV cure markers will be covered along with an assessment of HBV cure’s impact on HBV epidemiology and population health.

    COMPONENTS
    Online presentations comprised of PowerPoint slides and accompanying audio, evaluations, and continuing education credit claiming:
    - 19 online, narrated presentations 20 minutes in length 
    - Evaluation for CME credit/ABIM MOC point offerings 

    DIRECTIONS
    Review all section tabs before you begin. Start watching the presentation videos. Complete necessary components to claim either CME and ABIM and or ABP MOC.

    PRICING
    Member —  $175
    Trainee & Assoc. Members — $100
    Student Member —  $50
    Non-Member —  $225
    Any physician, scientist, or researcher with doctoral-level training who is not employed by Industry (pharma/device/etc.)
    Trainee & Assoc. Non-Member —  $150
    Any physician, scientist or researcher in a training program as certified by the director of their training program. This category also includes, but is not limited to, the degrees of MS, NP, PA, RN, and other related or comparable degrees.
    Student Non-Member —  $75
    Industry —  $450
    Any Industry (pharma/device/etc.) employee with or without medical training.
    Patient / Patient Advocate — Free

    CANCELLATION POLICY (Ended March 11,2021

    - Requests for cancellations must be submitted in writing to meetings@aasld.org.
    - Cancellations received through March 11, 2021 at 11:59 pm ET are subject to a 20% cancellation fee.
    - Cancellations received on March 12, 2021 and after are non-refundable.

    CONTINUING EDUCATION
    Continuing Medical Education (CME): 7.00 AMA PRA Category 1 Credits™
    ABIM Maintenance of Certification (MOC): 7.00 ABIM MOC Points

    HOW TO EARN AND CLAIM MOC POINTS
    To claim both CME Credits and ABIM MOC points for this activity you must:  

                 o    Watch each video presentation
                 o    Complete the Final Evaluation
                 o    Claim CME credits (ABIM Rule: MOC points must be equivalent to the amount of CME credits claimed for the activity.)

    MOC completions are collected on the 15th of each month and submitted to the ABIM by the last day of the month. Points are not submitted automatically and will not display immediately on your ABIM MOC Profile.
    MOC points are available for ABIM  board certified physicians only.

    Live Program Release Date: March 12, 2021
    OnDemand Program Release Date: May 14, 2021
    Expiration Date: December 31, 2021

    COPYRIGHT 
    All faculty in this activity have given their permission for publication ©2021 AASLD. 

    Upon completion of this activity, learners will be able to:

    • Identify populations to screen for HBV, to vaccinate, and to treat with focus on groups with controversial treatment indications.
    • Interpret results of new molecular and immunologic HBV cure biomarkers and learn about most updated HBV cure therapeutic development.
    • Detect areas of data gaps for future epidemiological, clinical, and translational research

    This activity was planned in the context of the following ACGME/IOM/IPEC competencies: Patient Care and Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement, Interpersonal and Communication Skills, Professionalism, Systems-based Practice, Provide Patient-centered Care, Work in Interdisciplinary Teams, Employ Evidence-based Practice, Apply Quality Improvement, Utilize Informatics, Values/Ethics for Interprofessional Practice, Roles/Responsibilities, Interprofessional Communication, Teams and Teamwork 

    • Hepatologists
    • Gastroenterologists
    • Nurses
    • Nurse Practitioners
    • Pharmacists
    • Physician Assistants
    • Transplant Coordinators
    • Surgeons
    • Fellows/Trainees
    • Infectious Disease Specialist
    • Public Health Workers/Stake Holders
    • Epidemiologists
    • Virologists 
    • Immunologists
    • Industry Stakeholders

    ACCREDITATION AND DESIGNATION STATEMENTS
    Continuing Medical Education (CME)

    The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. AASLD designates this live activity for a maximum of 7.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    American Board of Internal Medicine (ABIM)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 7.00 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

    CLAIMING CME CREDITS AND ABIM MOC POINTS
    CME Credits
    Physicians and other health care professionals seeking 7.00 AMA PRA Category 1 Credits™ for this live continuing medical education activity must complete an evaluation by Thursday, April 15. The CME evaluation will be available to you upon completion of the live streaming conference.

    MOC Points
    Physicians seeking ABIM and/or ABP MOC points must complete the CME and MOC evaluation by Thursday, April 15. Requests for MOC after this date will not be honored. The MOC evaluation is included in the CME evaluation.

    MOC Points will be reported to the ABIM by the end of October 2021 for attendees who successfully complete the MOC evaluation.

    DISCLOSURE OF CONFLICTS OF INTEREST
    AASLD requires all individuals who are in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosures are collected prior to the start of the educational activity. Any potential conflicts of interest that exist are resolved prior to implementation of the activity. All disclosures are made available and communicated to the leaner prior the activity beginning.

    The organizers and faculty have reported the following disclosures:

    Faculty

    Thomas Berg, MD, FAASLD
    Speakers Bureau: Abbvie, Bristol Myers Squibb, Gilead, Janssen, Merck, Novartis, Roche
    Scientific Consulting: Abbvie, Bristol Myers Squibb, Gilead, Merck/MSD, Janssen, Roche, Spring Bank
    Grants/Research Support: Abbvie, Bristol Myers Squibb,Boehringer Ingelheim, Gilead, Janssen, Merck/MSD, Novartis, Roche

    Robert S. Brown, MD, MPH, FAASLD
    Scientific Consulting: Gilead, AbbVie, Intercept, Shionogi
    Grants/Research Support: Gilead, AbbVie, Enanta, Intercept, Shionogi

    Kyong-Mi Chang, MD, FAASLD
    Advisory Board: Arbutus biopharma, Alnylam
    Scientific Consulting: Genentech

    Raymond T. Chung, MD, FAASLD
    Grants/Research Support: Abbvie, Merck, Boehringer Ingelheim, Gilead, Janssen, BMS, Roche, Synlogic, Kaleido, DSMB Alnylam (Uncompensated)

    Douglas T. Dieterich, MD, FAASLD
    Scientific Consulting: Gilead
    Grants/Research Support: Assembly

    Jordan J. Feld, MD, MPH, FAASLD
    Grants/Research Support: Abbvie, Alexion, Eiger, Enanta, Gilead, Janssen, Wako/Fujifilm
    Scientific Consulting: Abbvie, Arbutus, Deep Genomics, Eisai, Gilead, GSK, Roche

    Robert J. Fontana, MD, FAASLD
    Scientific Consulting: Sanofi
    Grants/Research Support: BMS, Gilead, Abbvie

    Marc G. Ghany, MD, MHSc, FAASLD
    Nothing to disclose.

    Robert G. Gish, MD, FAASLD
    Scientific Consulting: Abbott, AbbVie, Access Biologicals, Antios, Arena, Arrowhead, Bayer AG, Bristol-Myers Squibb Company, Dova, Dynavax, Eiger, Eisai, Enyo, eStudySite, Exelixis, Forty-Seven Inc, Genentech, Genlantis, Gerson Lehrman Group, Gilead Sciences, HepaTX, HepQuant, Intercept, Janssen, Laboratory for Advanced Medicine, Lilly, Merck, Salix, Shionogi, Spring Bank, Viking Therapeutics, Biocollections, Fujifilm/Wako, Quest
    Leadership in related society: Abbott, AbbVie, Merck, Arrowhead, Bayer, Dova Pharmaceuticals, Eiger, Enyo, Hatch BioFund, HepQuant, Intercept, Janssen, Medimmune
    Speakers Bureau: AbbVie, Bayer, BMS, Eisai, Gilead Sciences Inc., Intercept, Salix

    Yao-Chun Hsu, MD, MSc, PhD
    Grants/Research Support: Gilead Sciences
    Speakers Bureau: Abbvie, Bristol-Myers Squibb, Gilead Sciences, Merck Sharp & Dohme, and Novartis.
    Scientific Consulting: Gilead Sciences

    Ira M. Jacobson, MD, FAASLD
    Scientific Consulting: Abbvie, Arbutus, Arrowheard, Aligos

    Harry L.A. Janssen, MD, PhD, FAASLD
    Scientific Consulting: Arbutus, Enyo, Gilead Sciences, Janssen, Medimmune, Merck, Roche, Vir Biotechnlogy Inc., Viroclinics.
    Grants/Research Support: AbbVie, Arbutus, Bristol Myers Squibb, Gilead Sciences, Janssen, Medimmune, Merck, Roche

    Paul Kwo, MD, FAASLD
    Grants/Research Support: Gilead, Abbvie
    Scientific Consulting: Gilead, Abbvie

    Georg M. Lauer, MD, PhD
    Grants/Research Support: Janssen Pharma

    Seng Gee Lim, MD, MBBS, FAASLD
    Speakers Bureau: Gilead Sciences

    Anna S. Lok, MD, FAASLD
    Grants/Research Support: Bristol-Myers Squibb; Gilead; Target Pharma 
    Scientific Consulting: Huahui, Epigenomics, AIM, Ambys, Eli Lilly, Novo Nordisk, TARGET 
    Up To Date: Intellectual Property Rights 

    Mala Maini, MD
    Grants/Research Support: Gilead, Roche, Immunocore

    Paul Martin, MD, FAASLD
    Scientific Consulting: Abbvie, BMS, Merck, Gilead, Mallincrdot

    Brian J. McMahon, MD, FAASLD
    Nothing to disclose.

    Mindie H. Nguyen, MD, MAS, FAASLD
    Grants/Research Support: Gilead, B.K.Kee Foundation, NCI, Pfizer, Enanta, Vir, Glycotest 
    Scientific Consulting: Intercept, Eli Lilly, Exact Science (Amount received in 2020 was for service from 2019-2020 due to delay in payment. I am committed to not earn 10K or more a year in 2021 and after from this company or any other company during my term as part of the AASLD guidance writing group if selected)
    Leadership in related society: International Assoc for the Study of Liver Disease (Governing Council and Treasurer), Asian Health Foundation and Pacific Health Foundation (both 403c, Board  of Director); ACG (Clinical Practice Committee); AGA (Research Grant Panel); Gastro, APT, Lancet GI Hep, DDS, Life (Editorial Board); AFL Northern CA Chapter (Medical Advisory Board)

    George V. Papatheodoridis, MD, PhD, FAASLD
    Scientific Consulting: Abbvie, Dicerna, Gilead, Janssen, Merck Sharp & Dohme, Novartis, Roche, Spring-Bank 
    Grants/Research Support: Abbvie, Gilead, Janssen

    Barbara Rehermann, MD, FAASLD
    Nothing to disclose. 

    Norah Terrault, MD, MPH, FAASLD
    Grants/Research Support: Gilead Sciences, GSK, Roche-Genetech

    John Ward, MD
    Leadership in related society: Gilead Sciences, Abbvie, Abbott, Merck

    Heiner Wedemeyer, MD
    Scientific Consulting: Abbott, Abbvie, Altimmune, Biotest, Bristol Myers Squibb, BTG, Dicerna, Falk, Gilead, Janssen, MSD, MYR GmbH, Roche
    Grants/Research Support: Abbvie, Biotest, BMS, Gilead, Merck/MSD, Roche
    Speakers Bureau: Abbvie, Biotest, Janssen, MSD, Siemens

    Man-Fung Yuen, MD, PhD, DSc
    Scientific Consulting: AbbVie, Arbutus Biopharma, Bristol Myer Squibb, Dicerna Pharmaceuticals, GlaxoSmithKline, Gilead Sciences, Janssen, Merck Sharp and Dohme, Clear B Therapeutics, Springbank Pharmaceuticals, Roche

    Basic Research Committee
    Bernd Schnabl, MD, FAASLD
    Grants/Research Support: CymaBay Therapeutics, Synlogic Operating Company, BiomX, Axial Biotherapeutics; Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: Intercept Pharmacuticals, Ferring Pharmaceuticals, Patara Pharamaceuticals

    Laurie D. DeLeve, MD, PhD, FAASLD
    Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: Daiich Sankyo;  Intellectual Property Rights (Patents, Royalties, Licensing fees): COMPOSITIONS AND METHODS FOR AMELIORATING TISSUE INJURY, ENHANCING LIVER REGENERATION AND STEM CELL THERAPIES, 2017-230-01 US no. 62/544,589 End-organ selective MMP inhibition enhances bone marrow progenitor cell recruitment Southern California GBC ref.: 6177.132445PCT 

    Muyiwa Awoniyi, MD, PhD
    Nothing to disclose.

    Olivier Barbier, PhD, FAASLD
    Grants/Research Support: Canadian Institute for Health Research (public, Canada);

    Lily Dara, MD
    Nothing to disclose.

    Ariel E. Feldstein, MD
    Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: Gilead Merck ; Oppilan Pharma ; GSK

    Sandy Feng, MD, PhD
    Grants/Research Support: Novartis, Quark
    Leadership in related society: Board, Committee, Journal: Juno Therapeutics, Inc., America Journal of Transplantation, Immune Tolderance Network, OPTN/UNOS, The New England Journal of Medicine
    Stock/Stock Options: Amgen, Johnson & Johnson, Stryker, Abbott, Charles River Labs, Eli Lily, Express Scripts, Glaxo-Smith Klein, Medco, Merck, Pfizer, Hospira

    Mercedes Fernandez, PhD
    Nothing to disclose.

    Heather L. Francis, PhD, FAASLD
    Nothing to disclose.

    Rohit Kohli, MBBS, MS, FAASLD
    Speaker's Bureau: Alexion Pharmaceuticals
    Data Safety Monitoring Board for Industry or Commercial Enterprise: Takeda Pharmaceuticals
    Grants/Research Support: Epigen Pharma, Vision Pharmaceuticals
    Leadership in related society: NASPGHAN Foundation Board

    T. Jake Liang, MD, FAASLD
    Nothing to disclose.

    Pranoti Mandrekar, PhD, FAASLD
    Nothing to disclose.

    Laura E. Nagy, PhD, FAASLD
    Nothing to disclose.

    Kari Nejak-Bowen, MBA, PhD
    Nothing to disclose.

    Silvia M. Vilarinho, MD, PhD
    Nothing to disclose.

    Clinical Research Committee
    Ulrich Beuers, MD
    Nothing to disclose.

    Jasmohan S. Bajaj, MD, FAASLD
    Grants/Research Support: Valeant, Grifols
    Leadership in related society: Board, Committee, Journal: ACG: American Journal of Gastroenterology AE, AGA: Microbiome Scientific Advisory Board
    Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: Valeant, Norgine

    Therese Bittermann, MD
    Nothing to disclose

    Edward Doo, MD
    Nothing to disclose

    Andrea A. Gossard, APRN, CNP
    Nothing to disclose

    Gene Y. Im, MD
    Nothing to disclose

    Mariana Lazo, MD, PhD
    Nothing to disclose

    Rohit Loomba, MD
    Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: Glympse bio, Metacrine, Viking, Ini Pharma Ionis, Intercept, Ionis, Janssen Inc., Merck, NGM Biopharmaceuticals, Novo Nordisk, Pfizer, Madrigagal
    Grants/Research Support: Allergan, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, Galectin Therapeutics, Galmed Pharmaceuticals, GE, Genfit, Gilead, Intercept, Janssen, Madrigal Pharmaceuticals, Merck, NGM Disclosure updated: July      27, 2020 Biopharmaceuticals, Pfizer, and Siemens

    Arpan Arun Patel, MD
    Grants/Research Support: Gilead, Shire

    Shari S. Rogal, MD, MPH
    Nothing to disclose

    Emily J. Rothbaum Perito, MD
    Nothing to disclose

    Shimul A. Shah, MD
    Nothing to disclose

    Tracey G. Simon, MD
    Nothing to disclose

    James E. Squires, MD, MS
    Nothing to disclose

    Grace L. Su, MD, FAASLD
    Leadership in related society:  Member, Clinical Guidelines Committee, AGA; Company Employee, Officer, Director : My husband and son have equity interest in Applied Morphomics and Prenovo.

    Monica A. Tincopa, MD MSc
    Nothing to disclose

    Kymberly Watt, MD
    Expert testimony: Intercept - site- PI, Gilead - site PI, co-I, Conatus - site co-I, Novartis - previous site PI, co author study subanalysis, Pfizer- site co-I, all multicenter study related
    Stock/Stock Options: BMS; Arbutus; Madrigal; Viking

    AASLD Staff 
    Dominique Clayton
    Nothing to disclose

    Julie Deal
    Nothing to disclose 

    Matthew D’Uva
    Nothing to disclose

    Melanie Stanton
    Nothing to disclose

    Suzanne Thibeault
    Nothing to disclose

    Anne Wrobel
    Nothing to disclose 

    Thomas Berg

    Thomas Berg, MD, FAASLD is a Professor of Medicine at the University of Leipzig and Head of the Division of Hepatology for Leipzig University Medical Center, Germany. He specialized in internal medicine in 2001 and in Gastroenterology and Hepatology in 2007 at the University Medicine Berlin and became a lecturer in this subject in 2002.  His clinical and translational research is focused on chronic viral hepatitis, liver transplantation, hepatocellular carcinoma, genetics in liver disease, and liver failure, and he participated in numerous national and international clinical trials.

    Dr. Berg is Vice Secretary of the European Associations for the Study of the Liver (EASL), Board member of the EASL International Liver Foundation (EILF) and served the Journal of Hepatology as Co-Editor between 2014 and 2019.  He is also member of the American (AASLD), European (EASL), and German (GASL) Associations for the Study of the Liver, The European Society for Organ Transplantation (ESOT), The European Liver and Intestine Transplant Association (ELITA), German Transplantation Society (DTG), Working Group Internal Oncology (AiO), Working Group Gastroenterological Oncology (AGO), German Cancer Society (DKG), German Society of Gastroenterology (DGVS), and the representative of the DGVS in the foundation council of the German liver foundation. He has published more than 440 articles in peer-reviewed journals and more than 100 reviews and textbook contributions. His h-index is 76 (Scopus).

    Robert Brown

    RobertS. Brown, Jr., MD, MPH is Vice Chair of Transitions of Care and Clinical Chiefof the Division of Gastroenterology and Hepatology in the Department ofMedicine at Weill Cornell Medical College. He is also Professor of ClinicalMedicine at Columbia University College of Physicians & Surgeons. Dr. Brownis the Director of the Center for Liver Disease and Transplantation at NewYork-Presbyterian Hospital.

    Dr.Brown received his bachelor degree from Harvard College, his medical degreefrom New York University and his Master of Public Health from the GraduateSchool of Public Health, University of California in Berkeley. Following thecompletion of his medical degree, he fulfilled his internship in Medicine atBeth Israel Hospital in Boston and his fellowship in gastroenterology andhepatology at the University of California in San Francisco.

    Hehas co-authored more than 200 peer-reviewed articles and mentored many traineesand junior faculty. He is the incoming Editor-in-Chief of Liver Transplantation, an Associate Editor for Hepatology, and published abook, Common LiverDiseases and Transplantation: An Algorithmic Approach to Work-up and Management.Dr. Brown is the recipient of a Young Investigator Award from the AmericanSociety of Transplant Physicians, the Senior Attending Teacher Award fromColumbia University Medical Center, and the American Liver Foundation New YorkChapter's Physician of the Year.

    Kyong-Mi Chang

    Kyong-Mi Chang, MD, FAASLD is an Associate Professor of Medicine in the Division of Gastroenterology at the University of Pennsylvania Perelman School of Medicine, with administrative leadership role as the Associate Chief of Staff and Associate Dean for Research at the Philadelphia Corporal Michael J. Crescenz VA Medical Center (CMC VAMC). Dr. Chang received her MD and Internal Medicine residency training from the Medical College of Pennsylvania, followed by clinical GI fellowship training at the University of California in San Diego, also receiving her postdoctoral research training at the Scripps Research Institute studying CTL escape in HCV persistence. She has been a faculty member in GI Division at the University of Pennsylvania School of Medicine and the CMC VAMC since 1999 with active clinical and research activities. Her translational research focuses on immune pathogenesis in human hepatitis C and B virus infection with and without HIV coinfection—including various immune regulatory mechanisms such as FoxP3+ Tregs, IL-10+ Tr1 cells, gdT-cells, PD-1 and CTLA-4. Dr. Chang is also participating in the Million Veteran Program—a multi-center VA genomic study. She is a Fellow of the American Association for Study of Liver Disease (FAASLD) and a member of the American Society for Clinical Investigation (ASCI).

    Alfred S. Barritt

    Alfred Sidney Barritt IV, MD, MSCR is an associate professor in the UNC liver center at the University of North Carolina and is the interim medical director of liver transplantation and the transplant hepatology fellowship program director.  Dr. Barritt conducts clinical outcomes research in nonalcoholic fatty liver disease (NAFLD), general hepatology, and liver transplantation.  Dr. Barritt leads the UNC Liver Center’s clinical trial program in NAFLD where he is PI on multiple phase 2 and 3 industry sponsored clinical trials.  Dr. Barritt is a collaborator and advisor to multiple other investigators in the allied schools of health, including the Gillings School of Global Public Health, the Eshelman School of Pharmacy and the UNC School of Dentistry.  

    James J. Beaudoin

    James J. Beaudoin, PhD joined DILIsym Services, Inc., in 2020. He is involved in the ongoing development of the DILIsym modeling software, particularly the bile acid and cholestatic liver injury sub-models. He is also engaged in proprietary consulting projects including model development, simulations, and data analysis.

    Dr. Beaudoin received his PhD in Pharmaceutical Sciences from the University of North Carolina at Chapel Hill. His dissertation research focused on in vitro and modeling approaches to investigate mechanisms of DILI. Prior to his graduate training, he was a Data Coordinator II for the National NeuroAIDS Tissue Consortium, based at the University of Nebraska Medical Center. He obtained a M.S. in Molecular Medicine from Erasmus University Rotterdam, and a B.S. in Liberal Arts and Sciences from University College Utrecht, both based in the Netherlands. He also received pre-M.S. training in Biomedical Sciences from Leiden University, the Netherlands.

    Dr. Beaudoin has published over a dozen of scientific articles in the areas of drug and bile acid transporters, pharmacokinetics, drug toxicity, genetics of alcoholic hepatitis, and other human diseases. He received various awards during his academic training, including a NIH F31 Predoctoral Individual National Research Service Grant Award from NIDDK. He has been invited to speak at scientific and educational conferences, including the SOT Annual Meeting, the AAPS Drug Transporter Workshop, and the AACP Annual Meeting.

    James L. Boyer

    James L. Boyer, MD, FAASLD is the Ensign Professor of Medicine and Emeritus Director of the Liver Center at Yale University School of Medicine.  He is a graduate of Haverford College (1958) and the Johns Hopkins University School of Medicine (1962). From 1982 until 1996 he directed a combined Digestive Disease Section in the Department of Medicine at Yale.  He was the founding Director of the NIDDK funded Liver Center at Yale since 1984 and former Director of the NIEHS Center for Membrane Toxicity Studies at the Mt Desert Island Biological Laboratory in Salsbury Cove, ME where he was also Chairman of their Board of Trustees from 1995 to 2003 and 2011-2013.  He is past Chair, Board of Directors of the American Liver Foundation and a current member of Board of Mangers of Haverford College and Honorary Board member of the Mt Desert Island Biological Laboratory.  Dr. Boyer has a broad interest in all aspects of basic and clinical hepatology.  His laboratory has pioneered in understanding the cellular and molecular basis of bile formation and cholestasis and was supported by NIH for more than 40 years including two MERIT awards from NIDDK.  He is a member of the AASLD, ASCI, AAP, APS and ACCA and past president of both the American and the International Association for the Study of Liver Disease.  He is the recipient of Distinguished Achievement Awards from the AGA, AASLD and American Liver Foundation and the EASL International Recognition Award in 2020. 

    ​Nathaniel A. Brown

    Nathaniel A. Brown, MD is an Infectious Diseases physician with seven years’ fulltime employment in academic medicine (Asst Prof, UCLA School of Medicine, 1982-87; Assoc Prof, Cornell Medical College, 1987-89) followed by 31 years of pharmaceutic development experience, primarily in antiviral drug development (1989-2020).

     Dr. Brown studied Molecular Biophysics and Biochemistry as a Yale undergraduate and received his MD degree from Georgetown University School of Medicine. He completed clinical training in Pediatrics at The New York Hospital-Cornell Medical Center, and post-doctoral training in Infectious Diseases and Virology at Yale University School of Medicine.

    In his pharmaceutic career, Dr. Brown has had leadership roles in multiple Phase 1-3b clinical development programs, resulting in U.S. and global product approvals for six antiviral/anti-infective medicines:  two for hepatitis B, one for hepatitis C, two for HIV/AIDS, and one for Varicella.  He has extensive experience with globalized drug development, including North America, Europe, India, Southeast Asia, Japan, and China.  Now retired from fulltime work, his pharmaceutic positions included: Head, Opportunistic Infections Section, BurroughsWellcome Co. (1989-1994); Head, Hepatitis Section, GlaxoWellcome./GlaxoSmithKline (1994-2001); Chief Medical Officer positions at Idenix Pharmaceuticals (2001-2007), Presidio Pharmaceuticals (2009-2014), and Novira Therapeutics (2014-2016); and Chief Medical Advisor, Atea Pharmaceuticals (2018-2020).

    Dr. Brown has served in advisory roles for the Hepatitis B Foundation (Board of Directors), the NIH Div. of Extramural Grants, FDA’s Div. of Antiviral Products (Aug. 2002 HBV advisory meeting), and various pharma/biotech companies. He has chaired/co-chaired various scientific meetings, and authored/co-authored over 200 scientific articles, chapters, reviews, and abstracts.

    Naga P. Chalasani

    Naga P. Chalasani, MD, FAASLD currently serves as David W. Crabb Professor of Medicine and Interim Chair of the Department of Medicine at Indiana University School of Medicine. He previously served as the Director of the Division of Gastroenterology and Hepatology at the same institution from 2007 to 2020.   He completed his medical education in India and subsequently completed Internal Medicine Residency and Gastroenterology and Hepatology subspecialty training at Emory University in Atlanta. His research interests include CYP450 enzymes and liver disease and hepatic safety of xenobiotics. His research has been continuously funded by the National Institutes of Health since 1999.  He is currently the PI for three U01 awards and an R01 award from the National Institutes of Health. He published over 300 original papers, 3 Practice Guidelines, 47 book chapters/review articles, 31 editorials/commentaries, 16 symposium proceedings, and more than 500 abstracts. He is the lead author for the AASLD Practice Guideline on the Diagnosis and Management of Nonalcoholic Fatty Liver Disease and is the lead author on the ACG Practice Guideline on the Diagnosis and Management of Drug Induced Liver Injury. He is an elected member of the American Society of Clinical Investigation (ASCI) and the American Association of Physicians (AAP).

    Rachel Church

    Rachel Church, PhD is a Research Assistant Professor in the Department of Pharmacotherapy and Experimental Therapeutics within the Eshelman School of Pharmacy at the University of North Carolina, Chapel Hill. She also serves as the Director of UNC Organ Injury Biomarker Core that is part of UNC’s Institute for Drug Safety Sciences. Dr. Church received her B.S. degree from North Carolina State University and her Ph.D. from UNC Chapel Hill. Given the shortcomings of traditional measurements, the research of Dr Church aims to broaden the use and understanding of candidate biomarkers of organ injury, with a primary focus on clinical drug-induced liver injury. Dr. Church is also interested in identifying novel applications for traditional biomarkers that will improve their interpretation. Prior to joining UNC, Dr. Church was a Research Investigator at the Hamner Institutes for Health Sciences. 

    ​Robert J. Fontana

    Robert J. Fontana, MD, FAASLD, FAGA is a Professor of Medicine and Medical Director of Liver Transplantation at the University of Michigan.  He is a clinical-translational investigator with research interests in viral hepatitis, drug induced liver injury and acute liver failure.  He is co-chair of the Drug Induced Liver Injury Network (DILIN) Steering Committee and an active participant in the Hepatitis B Research Network.   He has also been an active member of the US Acute Liver Failure Study Group since 1998 and is a current Co-PI of this multicenter network.   

    Ira M. Jacobson

    Dr. Jacobson earned his BS from Yale University and MD from Columbia University College of Physicians and Surgeons. He trained as a fellow in gastroenterology and Hepatology at Massachusetts General Hospital and Harvard Medical School.  In 1984 he joined the faculty at Weill Cornell Medical College and New York Presbyterian Hospital.  During his 30 years at Weill Cornell, Dr. Jacobson served as Chief of the Division of the Gastroenterology and Hepatology from 1998-2015 as well as Medical Director of the Center for the Study of Hepatitis C. From 2015 to mid-2017 he was Chair of Medicine at Mount Sinai Beth Israel Medical Center, and Vice Chair of Medicine and co-Director of the Liver Institute at the Icahn School of Medicine at Mount Sinai.  He joined the faculty of NYU School of Medicine as Director of Hepatology on August 1, 2017.  

    Dr. Jacobson currently focuses on hepatitis B, fatty liver disease, and liver disease in Covid-19.  He has been an investigator in many trials on antiviral therapy for hepatitis B and C, including pivotal trials on interferon-based therapy and lead principal investigator and author for WIN-R trial (weight based ribavirin with peginterferon), ADVANCE (telaprevir), QUEST-1 (simeprevir), POSITRON (sofosbuvir), STARTVerso3 (faldaprevir), C-SALT (grazoprevir and elbasvir in advanced cirrhotics), and POLARIS-2 (sofosbuvir, voxilaprevir, velpatasvir) trials.    He has served on the Gastroenterology and Transplant Hepatology Boards of the American Board of Internal Medicine, as Associate Editor of the Journal of Hepatology, and as a reviewer for several other journals.  He has authored or co-authored over 250 peer-reviewed papers, chapters and reviews, including papers in the New England Journal of Medicine, Lancet, Gastroenterology, Hepatology, Journal of Hepatology, Journal of Viral Hepatitis, Clinical Gastroenterology and Hepatology, and served as Co-Chief Medical Editor of HCV Next. He has edited two books on ERCP and a volume on hepatitis B for Clinics in Liver Disease. 

    Paul H. Hayashi

    Paul “Skip” H. Hayashi, MD, MPH, FAASLD is an adult hepatologist at the FDA.  He is DILI Team Lead in the Division of Hepatology and Nutrition, Office of New Drugs, Center for Drug Evaluation and Research.  Prior to joining the FDA in February of 2020, he held positions in academia, civil service and uniformed service.  He received his BA in microbiology at University of California (UC) Los Angeles and medical degree at UC San Diego.  After completing residency and gastroenterology fellowship at UC Davis, he completed a clinical research fellowship in the Liver Diseases Section, National Institutes of Health, Bethesda, MD as a public health officer.  He then returned to California as Assistant Professor at the Veterans Administration Hospital in Loma Linda, California followed by serving in the US Air Force Medical Corp in Japan and Texas. While in the Air Force he continued clinical research, and then returned to academia by completing a transplant fellowship at the University of Colorado, Denver.  He then served as Assistant Professor and transplant hepatologist at Saint Louis University (SLU), St. Louis, Missouri.  In 2006, he completed a Master of Public Health at SLU.   From 2006, he was Medical Director of Liver Transplantation at the University of North Carolina (UNC), Chapel Hill, and became a Professor of Medicine at UNC before joining the FDA in 2020.  Since 2007, he has been a Co-Principle Investigator in the US Drug-Induced Liver Injury Network (DILIN) and remains Co-Chair of the DILIN’s Causality Committee.  

    Insook Kim

    Insook Kim, PhD is a clinical pharmacology team leader for gastroenterology and hepatology products in the Office of Clinical Pharmacology at FDA. Since she joined FDA as a clinical pharmacology reviewer in 2007, she has been involved in numerous IND and NDA review and has provided regulatory and scientific guidance for product development in the areas of gastroenterology, hepatology, and inborn errors of metabolism.  She served as a planning committee member for the public workshops on the clinical pharmacology and drug development for liver diseases, and the assessment of PK in hepatic impairment. Dr. Kim is a member of a guidance working group for hepatic impairment study.  Prior to joining FDA, Dr. Kim received a doctoral degree in Pharmaceutics from the University of Michigan and conducted post-doctoral research on nuclear receptors including FXR using transgenic animal models at the National Cancer Institute. She earned a master’s degree in Pharmacy from Seoul National University, and a bachelor’s degree in Pharmacy from Ewha Womens University in Korea.  Her area of interest is translational clinical pharmacology to optimize the drug development and therapeutics. 

    Gerd Kullak-Ublick

    Gerd Kullak-Ublick, MD is a Professor of Clinical Pharmacology and Toxicology at the University of Zurich and Department Head at the University Hospital Zurich, Switzerland. He additionally serves as the Global Head of Mechanistic Safety and Chair of the Hepatic Safety Team at Novartis Pharma, Basel. Dr. Kullak-Ublick went to medical school at the Universities of Bonn, Stanford, London and Munich and received his MD from Munich University in 1990.  Dr. Kullak-Ublick served his residency in Internal Medicine, Gastroenterology and Clinical Pharamacology/Toxicology at the University Hospitals of Munich and Zurich and conducted his postdoctoral research in Zurich, in collaboration with Allan Wolkoff at the Liver Centre, Albert Einstein College of Medicine, Bronx/New York. He obtained Board Certification in Internal Medicine (1998), Gastroenterology (2002) and Clinical Pharmacology and Toxicology (2005). He is coauthor of the 2019 EASL Clinical Practice Guideline on Drug-Induced Liver Injury, as well as on the 2020 CIOMS consensus report on Drug-Induced Liver Injury.

    Mala Maini

    Mala Maini, MD, PhD is a Professor of Viral Immunology in the Division of Infection and Immunity at UCL, London and works as a Consultant Physician in the viral hepatitis clinic. Her lab researches liver immunity and immunopathology, focusing on cellular interactions and metabolic constraints. By dissecting the immune correlates of viral persistence and liver damage, the Maini lab aims to contribute to the development of novel immunotherapeutic strategies for hepatitis B and hepatocellular carcinoma. Mala was awarded the Wellcome Trust Senior Investigator Awards in 2013 and 2019 and elected to the Academy of medical Sciences in 2016. Work in the Maini lab is also funded by the Cancer Research UK, EU Horizon 2020, Medical Research Foundation, NIHR, UKRI, British Infection Association.

    Victor J. Navarro

    Victor J. Navarro, MD, MHCM, FAASLD earned his MD from the Pennsylvania State College of Medicine and completed medical residency followed by chief residency in Internal Medicine at Temple University.  Thereafter, he obtained fellowship training in Gastroenterology, Hepatology, and Hepatobiliary Endoscopy at Yale University.  In 1994, he joined the faculty of the Yale University School of Medicine until he returned to Philadelphia in 2002, as Chief of Hepatology and Medical Director for Liver Transplantation at Thomas Jefferson University.  While at Jefferson, he started a Transplant Hepatology Fellowship program, and rose to the rank of Professor of Medicine, Pharmacology and Experimental Therapeutics.  In 2012, Dr. Navarro joined the Einstein Healthcare Network as Chairman of the Division of Hepatology, and Medical Director for Liver Transplantation. In 2016, he became the founding Medical Chair of the Department of Digestive Disease and Transplantation.  In 2019, Dr. Navarro was awarded his master’s in healthcare management from Harvard University.  He was named the Paul J. Johnson Chair for the Department of Medicine at Einstein in 2020 and is Professor of Medicine at the Sidney Kimmel Medical College, Philadelphia. 

     Dr. Navarro has over 130 publications including peer-reviewed scientific papers, topical reviews, and book chapters.  Dr. Navarro is funded by the National Institutes of Health for his work with the Drug Induced Liver Injury Network where he focuses on liver injury resulting from herbal and dietary supplements.  He is also funded by the Patient Centered Outcomes Research Institute as the Principal Investigator of a multi-site study designed to determine the optimal model for delivery of palliative care to patients with advanced stage liver disease.  

    Lorraine Pelosof

    Lorraine Pelosof, MD grew up in Dallas and graduated from The University of Texas at Austin. She completed her MD and her PhD in Molecular and Cell Biology at Washington University in St. Louis and then completed her Internal Medicine Residency at The University of Texas Southwestern Medical Center. Following residency, she did her fellowship training in Medical Oncology at Johns Hopkins where her research focused on DNA promoter methylation in gastrointestinal tumors.  After serving as an Assistant Professor in the Division of Hematology/Oncology at UT Southwestern, she moved back to Maryland where she is a Medical Officer on the GI oncology team in the Office of Hematology and Oncology Products at the U.S. Food and Drug Administration. 

    William Proctor

    Will Proctor, PhD, DABT is a Senior Scientist and Senior Director of Predictive Toxicology in the Department of Safety Assessment at Genentech, Inc. Prior to joining Genentech in 2013, Dr. Proctor earned his BS in Chemistry from Trinity College  and PhD in Pharmaceutical Sciences from the University of North Carolina at Chapel Hill in the laboratory of Dr. Dhiren Thakker with a focus on drug transport and pharmacokinetics.  He then performed postdoctoral training at the National Institutes of Health in the laboratory of Dr. Lance Pohl, with research centered on immune mechanisms of drug-induced liver injury (DILI). Will is a board-certified toxicologist and organizational leader with 10 years of experience in investigative and discovery toxicology. At Genentech, Dr. Proctor serves as the Senior Director of Predictive Toxicology, where he oversees the Investigative Toxicology Laboratory, Complex In Vitro Systems Laboratory, and non-clinical safety support for the Small-Molecule Drug Discovery (SMDD) organization. He is also actively involved in several cross-pharma consortia, with leadership roles in the Innovation and Quality (IQ) Microphysiological Systems Affiliate and the Non-clinical Working Group of the IQ DILI Affiliate.  In addition to these activities, Will has continued his research in mechanisms of DILI, including identifying and qualifying preclinical tools to better assess hepatotoxicity risk during drug discovery. 

    K. Rajender Reddy

    K. Rajender Reddy, MD, FAASLD is the Ruimy Family President’s Distinguished Professor of Medicine and Professor of Medicine in Surgery in the Division of Gastroenterology/Hepatology at the University of Pennsylvania. He is the Director of Hepatology, Medical Director of Liver Transplantation, and the Director of the Viral Hepatitis Center. He is a Fellow of the American College of Physicians, American College of Gastroenterology, the Royal College of Physicians, and the American Association for the Study of Liver Diseases. He has held several Visiting Professorships at Medical Schools throughout the World. He has trained and mentored, over the years, several fellows and research assistants, towards a career path in health care and research. He served on several committees for AASLD and was a Councilor-at-Large for 3 years. Dr. Reddy is also a recipient of AASLD’s Distinguished Educator/Mentor Award in 2019.

    Dr. Reddy has authored or co-authored several papers on a spectrum of hepatobiliary topics that include liver transplantation, chronic C viral hepatitis, acute on chronic liver failure, and hepatocellular carcinoma. In addition, he has edited and contributed to several textbooks, and has participated in numerous scientific presentations at National and International meetings. He has been the recipient of both federal and non-federal funding for clinical research.      

    Arie Regev

    Arie Regev, MD, FAASLD is a gastroenterologist and hepatologist working in the Global Patient Safety organization of Eli-Lilly and Company. He heads Lilly’s Safety Advisory Hub and is the chair of Lilly’s Liver Safety Advisory Committee. Dr. Regev is the founding co-chair of the IQ-DILI initiative, and a co-chair of the CIOMS DILI working group. He is a member of the steering committee and a co-chair the immunotherapy working group of the IQ DILI initiative. Dr. Regev is an associate professor of medicine at the division of gastroenterology and hepatology of Indiana University School of Medicine. Prior to joining Eli-Lilly he was an associate professor of medicine and director of the hepatology training program of the University of Miami School of Medicine.

     Dr. Regev received his MD from the Hebrew University in Jerusalem, Israel. He completed residency in medicine and fellowship in gastroenterology at Rabin Medical Center and Tel Aviv University, and completed clinical fellowship in hepatology and transplant hepatology at the division of hepatology of the University of Miami, Florida.

     Dr. Regev has conducted numerous clinical trials in the field of viral hepatitis, liver transplantation, and drug induced liver injury. He was the principal investigator of several NIH funded and industry supported clinical trials in the areas of viral hepatitis, nonalcoholic fatty liver disease, drug induced liver injury, and liver transplantation. He is the author of numerous publications in major medical journals and several chapters in leading medical textbooks. Dr. Regev received teaching and research awards at the University of Miami and Tel Aviv University. He joined Eli-Lilly and the Global Patient Safety organization in 2007.

    Mark W. Russo

    Mark W. Russo, MD, MPH, FAASLD is Medical Director of Liver Transplantation, Chief, Division of Hepatology, and Clinical Professor of Medicine at Carolinas Medical Center-Atrium Health. At the American Association for the Study of Liver Diseases, Dr. Russo is Chair of the Maintenance of Certification Committee, member of the Nominating Committee, co-director of the 2020 AASLD Transplant Hepatology Board Review course, and member of a working group planning for the future hepatology workforce. He is an Associate Editor for the American Journal of Gastroenterology and serves on the editorial board of Expert Reviews in Gastroenterology and Hepatology and the Journal of Clinical Medicine.  He has more than 100 peer-reviewed publications and editor of the textbook Diagnosis and Management of Autoimmune Hepatitis.

    Walter L Straus

    Walter L Straus, MD, MPH, FACP is Associate Vice-President and Therapeutic Area Head for Vaccines and Infectious Disease Therapeutics within Global Clinical Safety and Pharmacovigilance at Merck & Co., Inc. In this capacity his team is responsible for overseeing safety assessment of clinical research as well as post-licensure safety monitoring and assessment for the portfolio of Merck vaccines and infectious disease therapeutics.  

     His training includes Harvard College (A.B.) medicine (SUNY-Buffalo and The Johns Hopkins University), gastroenterology/hepatology (UNC-Chapel Hill), and epidemiology (The Johns Hopkins University). He was formerly on staff at the National Center for Infectious Diseases at the CDC (Atlanta), and is a current member of US HHS Secretary’s Advisory Board on Human Research Protection (SACHRP). At Merck, he oversees the company’s Organ-Specific Safety Boards, which is an internal resource providing sub-specialty expertise to product development teams.  

    Jack Uetrecht

    Jack Uetrecht, PhD is Professor of Pharmacy and Medicine and held the Canada Research Chair in Adverse Drug Reactions from 2001 to 2015.  His research is focused on the mechanisms of idiosyncratic drug reactions with an emphasis on reactive metabolites and immune mechanisms, and he consults for the pharmaceutical industry on problems with idiosyncratic drug reactions. He received his PhD in organic chemistry at Cornell University in 1972, MD at Ohio State University in 1975, and did his internal medical residency at the University of Kansas Medical Center from 1975-1978.  He completed his clinical pharmacology fellowship in 1981 at Vanderbilt University and then joined the faculty as an assistant professor.  He moved to the University of Toronto in 1985 as an associate professor and was the associate dean of pharmacy from 1994 to 1998.  He is a Fellow of the American College of Physicians and Canadian Academy of Health Sciences.  He received the Janssen-Ortho Research award in 2001, the Student’s Administrative Council Undergraduate Teaching Award in 2005, and was voted Teacher of the Year by the 3rd year class in both 2007 and 2008.  He received the Vos Award for Lifetime Career Achievement in Immunotoxicology from the Society of Toxicology in 2018 and the STC Gabriel Plaa Award of Distinction in 2019.  He has over 170 research publications, 35 book chapters, and has published a book with Bill Trager on drug metabolism.  

    Elizabeth C. Verna

    Elizabeth C. Verna, MD, MS is an Associate Professor of Medicine in the Center for Liver Disease and Transplantation and Division of Digestive and Liver Diseases at Columbia University, where she practices as transplant hepatologist. In addition, Dr. Verna has an active clinical research program in end-stage liver disease and liver transplantation and is the Director of Clinical Research for the Columbia University Transplant Clinical Research Center. 

  • Fundamentals of Liver Disease - Hepatitis C 2.0

    Contains 28 Component(s), Includes Credits Recorded On: 02/26/2021

    The overall goal is to improve patient care by increasing learner competence and confidence in both proper patient identification and assessment and increasing learner performance in therapeutic options and on-treatment management strategies for patients. Patient outcomes will be improved as a result of the improvements in more providers understanding these key components in the management and care of patients with liver diseases.

    DESCRIPTION
    There is currently an anticipated shortage of trained providers capable of diagnosing and treating different liver diseases. As a result of this increased demand and limited specialists in the field, more and more front-line providers are faced with these patients and do not have the experience or resources that will allow them to manage them appropriately.

    The overall goal is to improve patient care by increasing learner competence and confidence in both proper patient identification and assessment and increasing learner performance in therapeutic options and on-treatment management strategies for patients. Patient outcomes will be improved as a result of the improvements in more providers understanding these key components in the management and care of patients with liver diseases.

    KEY TOPIC AREAS
    HCV: Epidemiology and Screening
    Patient with New Diagnosis of HCV (anti-HCV positive)
    Assessing Severity of Liver Disease in HCV
    Management of the Patient with Chronic HCV
    Management of the Chronic HCV Patient with Co-Morbid and Other Conditions
    Antiviral Treatment of the Patient with HCV Infection
    Management of Patients with HCV who have Achieved a Virological "Cure"
    The Pediatric Patient with HCV

    Release date: February 26, 2021
    Expiration date: February 25, 2024
    Time to complete each module: 30 minutes

    CREDITS OFFERED
    Continuing Medical Education (CME): For a maximum of 4.00 AMA PRA Category 1 Credits™  
    Continuing Education (CE): For a maximum of 4.00 Contact Hour 
    You may only earn one Continuing Education Credit type - either CME or CE

    Maintenance of Certification (MOC): For a maximum of 4.00 MOC Points

    COMPONENTS
    Online presentations comprised of:

    -8 online interactive, narrated modules 15 to 20 minutes in length
    -Pre- and post-test questions for each module
    -Evaluation for CME or CE credit offering 

    DIRECTIONS
    Click "Register" to activate the enduring material. Review all section tabs before you begin. Select module of interest. Complete all components to claim either CME or CE. MOC is available for learners who complete and earn CME.

    COPYRIGHT 
    All faculty in this activity have given their permission for publication ©2021 AASLD. 

    CONTACT INFORMATION 
    For questions on CME and MOC content or LiverLearning®, contact online_education@aasld.org 
    For questions on CE credit for this enduring material, contact Certificate@AmedcoEmail.com

    Learning Objectives:
    • Identify patients with liver disease
    • Apply diagnostic tests appropriately
    • Discuss important counseling
    • Recognize treatment/referral priorities
    • Identify first line therapies for different liver diseases
    • Refer to specialist in a timely and appropriate fashion

    This curriculum was developed for Primary Care Providers and any other healthcare provider interested in liver disease.

    Hepatologists
    Gastroenterologists
    Nurses
    Nurse Practitioners
    Pharmacists
    Physician Assistants
    Transplant Coordinators
    Surgeons
    Fellows/Trainees
    Primary Care Physicians
    Other healthcare providers

    CREDITS OFFERED 
    Continuing Medical Education (CME): For a maximum of 4.00 AMA PRA Category 1 Credits™ 
    Maintenance of Certification (MOC): For a maximum of 4.00 MOC Points
    Continuing Education (CE): For a maximum of 4.00 Contact Hours

    ACCREDITATION AND DESIGNATION STATEMENTS 
    Continuing Medical Education (CME) 
    The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. AASLD designates this enduring activity for a maximum of 4.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Maintenance of Certification (MOC) 
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4.00 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    image

    Continuing Education (Nursing Contact Hours)  
    In support of improving patient care, this activity has been planned and implemented by Amedco LLC and the American Association for the Study of Liver Diseases.  Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Credit Designation Statement – Amedco LLC designates this enduring material activity for a maximum of 4.00 contact hours for nurses. Learners should claim only the credit commensurate with the extent of their participation in the activity.

    CLAIMING CME CREDITS 
    Physicians and other health care professionals for a maximum of 4.00 AMA PRA Category 1 Credits™ for this enduring continuing medical education material must completed by February 25, 2024

    CLAIMING CE CREDITS
    Nurses for a maximum of 4.00 contact hours for this enduring continuing education material must be completed by February 25, 2024

    CLAIMING ABIM MOC POINTS  
    Physicians seeking ABIM MOC credit must complete the enduring material by February 25, 2024. Requests for MOC after this date will not be honored. MOC Points will be reported to the ABIM by the end of each month through February 2024 for individuals who successfully complete MOC.

    HOW TO EARN AND CLAIM MOC POINTS For each module that you wish to claim MOC points for you must:

                 o    Complete the pre-tests

                 o    Watch video presentations

                 o    Complete the post-tests and pass with a score of 70% or higher (Participants have unlimited attempts to earn the passing  score.)

                 o    Claim CME credits (ABIM Rule: MOC points must be equivalent to the amount of CME credits claimed for the activity.)

    MOC completions are collected on the 15th of each month and submitted to the ABIM by the last day of the month. Points are not submitted automatically and will not display immediately on your ABIM MOC Profile.

    MOC points are available for ABIM board certified physicians only.

    DISCLOSURE OF CONFLICTS OF INTEREST 
    AASLD requires all individuals who are in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosures are collected prior to the start of the educational activity. Any potential conflicts of interest that exist are resolved prior to implementation of the activity. All disclosures are made available and communicated to the leaner prior the activity beginning.

    The enduring material organizers, faculty, reviewers and staff have reported the following disclosures:

    John W. Ward, MD
    Faculty
    General non-binding support: Abbott, Roche, AbbVie, Siemens, AASLD, EASL, Zydus Cadilla, Cepheid, Asian Liver Center, John Martin Foundation, Gilead Sciences, US CDC, PHARCO and individuals

    Nancy Reau, MD, FAASLD
    Faculty
    Grant/Research Support: AbbVie, Gilead Sciences
    Faculty/Advisory Committee or Review Panels: AbbVie, Gilead Sciences

    Jordan J. Feld, MD, MPH, FAASLD
    Faculty
    Grant/Research Support: AbbVie, Eiger, Enanta, Gilead Sciences, Janssen and Wako/Fujifilm
    Faculty/Advisory Committee or Review Panels: AbbVie, Arbutus, Eisai, Gilead Sciences, GSK and Roche

    Sanjeev Arora, MD, FAASLD
    Faculty
    Nothing to disclose

    Raymond T. Chung, MD, FAASLD
    Faculty
    Grant/Research Support: AbbVie, Gilead Sciences, Merck, BMS, Janssen, Boehringer and Roche

    Jennifer Price, MD, PhD
    Faculty
    Grant/Research Support: Gilead Sciences and Merck
    Consulting: Theratechnologies
    Ownership Interest (Spouse): AbbVie, Bristol-Myers Squibb, Johnson and Johnson and Merck

    Michael W. Fried, MD, FAASLD
    Grant/Research Support: AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck and multiple NIH Grants
    Consulting: AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen and Merck

    Andrew J. Muir, MD, FAASLD
    Grant/Research Support: AbbVie, Gilead Sciences and Merck
    Faculty/Advisory Committee or Review Panels: AbbVie and Gilead Sciences

    Kathleen B. Schwarz, MD, FAASLD
    Grant/Research Support: NIDDK, Roche/Genentech and Gilead Sciences
    Consulting: Sarepta, Up-to-Date and Mirium 

    Lauren A. Beste, MD
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Nothing to disclose 

    Amanda J. Chaney, DNP, APRN, FNP-BC
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Royalities: Springer Publishing-Author 

    Rena Fox, MD 
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Grant/Research Support: Gilead Sciences

    Leslie Hayes, MD 
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Nothing to disclose 

    Sonal Kumar, MD
     
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Scientific Consultant/Advisory to Industry or Commercial Enterprise, including Development of educational Presentations: Gilead Sciences, Intercept and AbbVie 
    Speaker's Bureau: Gilead Sciences and AbbVie
    Grant/Research Support: Gilead Sciences, AbbVie and Intercept

    Adam Mikolajczyk, MD 
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Nothing to disclose

    Amol Rangnekar, MD 
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Nothing to disclose

    Raj Vuppalanchi, MD, FAASLD 
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Data Safety Monitoring Board for Industry or Commercial Enterprise: Enanta, Enyio and LabCorp/Covance Served as PI for multicenter clinical trials: Intercept, Gilead, Zydus Discovery, Novo Nordisk and Eli Lilly

    Susan Zapatka, DNP 
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Nothing to disclose

    Dominique Clayton 
    AASLD Staff
    Nothing to disclose

    Denise Seise
    AASLD Staff
    Nothing to disclose

    Sheryl Morgan 
    Amedco LLC Staff
    Nothing to disclose

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    DISCLAIMER
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

    Acknowledgement of Commercial Support:
    No commercial support was received for this enduring material activity.


  • 2021 Webinar: Use of Serum and Imaging Biomarkers of NAFLD/NASH in Clinical Practice

    Contains 2 Component(s) Recorded On: 02/17/2021

    Webinar hosted by the Nonalcoholic Fatty Liver Disease Special Interest Group on February 17, 2021.

    This on-demand webinar will update the audience on the most recent data in non-invasive testing (NITs) biomarkers in NAFLD/NASH (including use for staging, monitoring disease progression and response to therapy). We will focus on three key areas: serum-based biomarkers, imaging-based biomarkers and how to use combination or sequential NITs. At the conclusion of the webinar, learners will have an update on knowledge of various biomarkers in NAFLD and a path to apply best practices in their setting.

    Emmanuel A. Tsochatzis

    Emmanuel A. Tsochatzis, MD, PhD, MSc, FEBTM, FRCP is a professor of hepatology at the UCL Institute for Liver and Digestive Health in the Royal Free Hospital, London, UK and head of the Centre for Metabolic Liver Diseases. He leads the specialist multidisciplinary service in NAFLD at the Royal Free Hospital and has an active research program in NAFLD. His clinical and research interests include NAFLD, non-invasive fibrosis assessment, cirrhosis and portal hypertension. Professor Tsochatzis finished his specialty training and PhD in Hippokration General Hospital in Greece, before moving to the Royal Free Hospital for his post-doc research under Professor Andy Burroughs. Since 2019, he is a member of the Scientific Committee and Governing Board of EASL.

    Professor Tsochatzis is the section editor for liver disease in BMC Gastroenterology and in the editorial board of Liver International. He was a member of the editorial board of HEPATOLOGY from 2017 to 2019. He is a member of the steering committee of the Baveno collaboration for portal hypertension. He led several international research collaborations resulting in more than 220 publications in peer reviewed journals. His work on the cost-effectiveness of non-invasive fibrosis tests has informed the WHO guidelines on diagnosis and treatment of both HBV and HCV. He designed and implemented a primary care pathway for NAFLD referrals to secondary care. He received funding for his research from NIHR, EASL and EU Horizon 2020.

    Mohammad Shadab Siddiqui

    Mohammad Shadab Siddiqui, MD is an associate professor of medicine at Virginia Commonwealth University in the Division of Gastroenterology and Hepatology. His clinical and research interest are largely in nonalcoholic fatty liver disease (NAFLD). More specifically, he is interested in the liver-heart axis and metabolic complications of NAFLD. This research spans full spectrum on NAFLD that includes early disease, cirrhosis and post-LT NAFLD. He also has an interest in biomarker development and regulatory science. In his publications, he demonstrated the impact that NAFLD has on lipoprotein metabolism and the clinical implications of this impact. His work in the cirrhosis cohort attempted to better define cardiovascular risk assessment prior to liver transplantation. Furthermore, his publications have also provided additional insight on CVD after LT.

    Dr. Siddiqui is a member of the Liver Forum and was the lead author on the NAFLD Case Definition manuscript. He is part of the AASLD Liver Transplantation Education Committee. Additionally, he is an active member of the AASLD NAFLD and Liver Transplantation SIG. He remains active within the NAFLD research space serving as the site-PI for multiple clinical trials and was the national PI for the multi-center NASH trial for the saroglitazar. He is also an active member of the NailNASH consortium, which is a multi-center collaboration between academic centers across the US that aims to better understand post-liver transplant NAFLD. In addition to his clinical and research involvement, he is an active teacher and educator at Virginia Commonwealth University. He mentors many trainees from undergraduates, post-graduate and medical students, residents and fellows.

    Alina M. Allen

    Alina M. Allen, MD is an assistant professor of medicine in the Division of Gastroenterology and Hepatology and the director of the NAFLD Clinic at Mayo Clinic Rochester, Minnesota. She is an NIH-funded investigator in the field of nonalcoholic fatty liver disease (NAFLD) with clinical expertise in liver diseases before and after liver transplantation. Her research interest includes the development of noninvasive biomarkers for the diagnosis of nonalcoholic steatohepatitis (NASH) and pathways to improve the identification and management of patients with NAFLD. Her research program includes biorepositories/biomarker databases, longitudinal population-based studies of natural history and clinical trials.

    Dr. Allen is actively involved in national societies as a member of the NAFLD Special Interest Group within the American Association for the Study for Liver Diseases (AASLD) and as a GRADE methodologist of the Clinical Practice Guideline Committee of the American Gastroenterology Association. She serves on the Editorial Board of HEPATOLOGY, the AASLD Publications Committee and the Annual Meeting Education Committee. She has served as chair of the AGA Abstract Committee for Non-Alcoholic Fatty Liver Diseases (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) for the past three years.

    Kathleen E. Corey (Moderator)

    Kathleen E. Corey, MD, MPH, MMSc is the Director of the MGH Non-Alcoholic Fatty Liver Disease (NAFLD) Clinic, Associate Program Director for the Medicine Residency for Clinical and Translational Research, a hepatologist who specializes in NAFLD, Physician Investigator in the CTEU, and an Assistant Professor of Medicine at HMS.

     Dr. Corey’s interests include clinical and translational research in NAFLD. She aims to better understand predictors of development and progression of NAFLD, the interplay between cardiovascular disease and NAFLD and the natural history of NAFLD in persons living with HIV (PLWH). She is the Co-PI for an R01 evaluating the role of tesamorelin, a growth hormone-releasing hormone for the treatment of NAFLD and is involved in an NIH-funded study on the prevalence, risk factors and treatment of NAFLD in PLWH.

     Dr. Corey earned her MD at Duke University School of Medicine, her MPH from the University of North Carolina and her MMSc from Harvard Medical School. Prior to joining the faculty of MGH, she completed her training in Internal Medicine, Chief Residency, Gastroenterology and Advanced Hepatology and Liver Transplant at MGH.

  • 2021 Webinar: Developing a Career in Clinical Research

    Contains 2 Component(s) Recorded On: 02/10/2021

    Webinar hosted by the Hepatitis B Special Interest Group on February 10, 2021.

    This live webinar will focus on identifying areas of unmet needs and developing a research career. We will have four presenters share their career experiences. An experienced professional will share her experience on doing clinical research in hepatitis B and thoughts on selecting between research, quality improvement or medical educator. Three young investigators will present their perspectives on how his or her career started and share in future career plans.

    Gerd Kullak-Ublick

    Gerd Kullak-Ublick, MD is a Professor of Clinical Pharmacology and Toxicology at the University of Zurich and Department Head at the University Hospital Zurich, Switzerland. He additionally serves as the Global Head of Mechanistic Safety and Chair of the Hepatic Safety Team at Novartis Pharma, Basel. Dr. Kullak-Ublick went to medical school at the Universities of Bonn, Stanford, London and Munich and received his MD from Munich University in 1990.  Dr. Kullak-Ublick served his residency in Internal Medicine, Gastroenterology and Clinical Pharamacology/Toxicology at the University Hospitals of Munich and Zurich and conducted his postdoctoral research in Zurich, in collaboration with Allan Wolkoff at the Liver Centre, Albert Einstein College of Medicine, Bronx/New York. He obtained Board Certification in Internal Medicine (1998), Gastroenterology (2002) and Clinical Pharmacology and Toxicology (2005). He is coauthor of the 2019 EASL Clinical Practice Guideline on Drug-Induced Liver Injury, as well as on the 2020 CIOMS consensus report on Drug-Induced Liver Injury.

    Kali Zhou

    Kali Zhou, MD, MAS is a transplant hepatologist and assistant professor in the Division of Gastrointestinal and Liver Diseases, Keck School of Medicine, University of Southern California, Los Angeles, California. She received her medical degree from Feinberg School of Medicine at Northwestern University, completed an internal medicine residency at the University of California, Los Angeles, and a T32 gastroenterology and transplant hepatology fellowship at the University of California, San Francisco, where she also completed a master’s in clinical research. She holds committee positions in the AASLD HBV and Public Health SIGs.

    Dr. Zhou investigated the epidemiology of HCV in Southern China as a Fulbright scholar and has published numerous peer-reviewed manuscripts and reviews related to epidemiology and health services delivery for chronic HBV infection. Her current research program focuses on disparities in liver cancer and utilizing novel geospatial approaches to improve cancer equity and outcomes for multi-ethnic populations. She is also grant funded to study the impact of immigration and acculturation on completing guideline-based HBV metrics. She was awarded the Early Career Investigator Award in Clinical/Translational Science by AASLD for her work.

    Hannah Lee

    Hannah Lee, MD is an assistant professor of medicine at Virginia Commonwealth University Medical Center in Richmond, Virginia in the division of GI, Hepatology and Nutrition. She has a strong interest in liver cancer and viral hepatitis, particularly hepatitis B. She was previously the director of the Asian Pacific Liver Health Program in Boston Chinatown at Tufts Medical Center. She is currently co-director of the multidisciplinary liver cancer program at VCU and practices both transplant and general hepatology. She is involved in multicenter studies evaluating the natural history of HBV and HCC.

    Dr. Lee’s career has been focused on addressing health disparities in liver disease, particularly among disproportionately affected minority groups with chronic hepatitis B. Some of her work has focused on screening and linkage to care. She has been involved in education and outreach both locally and nationally in addressing liver health disparities in hepatitis B and hepatocellular carcinoma among various communities in the United States. Dr. Lee currently serves on the AASLD Hepatitis B Special Interest Group's Leadership Steering Committee and is co-chair of the Education Subcommittee. She also serves as a committee member on the AASLD Public Policy Committee.

    ​Robert J. Fontana

    Robert J. Fontana, MD, FAASLD, FAGA is a Professor of Medicine and Medical Director of Liver Transplantation at the University of Michigan.  He is a clinical-translational investigator with research interests in viral hepatitis, drug induced liver injury and acute liver failure.  He is co-chair of the Drug Induced Liver Injury Network (DILIN) Steering Committee and an active participant in the Hepatitis B Research Network.   He has also been an active member of the US Acute Liver Failure Study Group since 1998 and is a current Co-PI of this multicenter network.   

    William Proctor (Moderator)

    Will Proctor, PhD, DABT is a Senior Scientist and Senior Director of Predictive Toxicology in the Department of Safety Assessment at Genentech, Inc. Prior to joining Genentech in 2013, Dr. Proctor earned his BS in Chemistry from Trinity College  and PhD in Pharmaceutical Sciences from the University of North Carolina at Chapel Hill in the laboratory of Dr. Dhiren Thakker with a focus on drug transport and pharmacokinetics.  He then performed postdoctoral training at the National Institutes of Health in the laboratory of Dr. Lance Pohl, with research centered on immune mechanisms of drug-induced liver injury (DILI). Will is a board-certified toxicologist and organizational leader with 10 years of experience in investigative and discovery toxicology. At Genentech, Dr. Proctor serves as the Senior Director of Predictive Toxicology, where he oversees the Investigative Toxicology Laboratory, Complex In Vitro Systems Laboratory, and non-clinical safety support for the Small-Molecule Drug Discovery (SMDD) organization. He is also actively involved in several cross-pharma consortia, with leadership roles in the Innovation and Quality (IQ) Microphysiological Systems Affiliate and the Non-clinical Working Group of the IQ DILI Affiliate.  In addition to these activities, Will has continued his research in mechanisms of DILI, including identifying and qualifying preclinical tools to better assess hepatotoxicity risk during drug discovery. 

    Yee Hui Yeo (Moderator)

    Yee Hui Yeo, MD, MSc is a resident doctor at Cedars-Sinai Medical Center. He is an active investigator on viral hepatitis related epidemiological and health outcomes research. He is currently a trainee member of the Hepatitis B SIG Steering Committee, AASLD. He has published more than 40 peer-reviewed publications, including first or co-first authorship of original articles published in Gastroenterology, Journal of Hepatology, HEPATOLOGY and Gut.

    Dr. Yeo has served as associate editor for BMC Gastroenterology. He is interested in harnessing health data analytic tools, modeling, and meta-analysis to determine the epidemiology, cascade of care, natural history, and outcomes of chronic viral hepatitis infection. He uses large databases, multicenter cohorts and EHR data from Cedars-Sinai Medical Center. He has been participating in international consortia of natural history of hepatitis B infection. His works were selected as "Best of the Liver Meeting" in AASLD annual meeting 2018. Yeo is the recipient of "Emerging Liver Scholar Award" in 2019.

  • 2021 Webinar: To Stop or Not to Stop: The Practice of Finite Nucleos(t)ide Analog Therapy

    Contains 2 Component(s) Recorded On: 01/20/2021

    Webinar hosted by the Hepatitis B Special Interest Group on January 20, 2021.

    This one-hour webinar will summarize the data that supports the finite strategy of nucleos(t)ide analog (NA) therapy in patients with chronic hepatitis B. Further discussion on how the presenter practices the strategy. In the second half of the webinar, the presenter will present data that argues against the rationale of a finite NA therapy. The presenter will elaborate on why stopping NA before loss of HBsAg cannot be recommended. We will conclude with a twenty-minute discussion on the gaps in current knowledge, whether and how the practice can be individualized.

    Wen-Juei Jeng

    Rachel Wen-Juei Jeng, MD received her Doctor of Medicine Education from College of Medicine, National Yang-Ming University, Taiwan (1998-2005). She has accomplished internal medicine residency, Gastroenterology fellowship training and becomes a faculty and physician scientist in Department of Gastroenterology and Hepatology in Chang Gung Memorial Hospital, Linkou branch, Taiwan. She currently serves as an Associate Professor in College of Medicine, Chang Gung University since 2019.

    Dr. Jeng’s research interests mainly focus on viral hepatitis (esp. HBV) and clinical hepatology. She has been working with her mentor Prof. Yun-Fan Liaw and published a series of off-Nuc therapy cohort study in Hepatology and Clinical Gastroenterology and HEPATOLOGY. She now serves as a member of TASL, EASL and AASLD.

    Paul H. Hayashi

    Paul “Skip” H. Hayashi, MD, MPH, FAASLD is an adult hepatologist at the FDA.  He is DILI Team Lead in the Division of Hepatology and Nutrition, Office of New Drugs, Center for Drug Evaluation and Research.  Prior to joining the FDA in February of 2020, he held positions in academia, civil service and uniformed service.  He received his BA in microbiology at University of California (UC) Los Angeles and medical degree at UC San Diego.  After completing residency and gastroenterology fellowship at UC Davis, he completed a clinical research fellowship in the Liver Diseases Section, National Institutes of Health, Bethesda, MD as a public health officer.  He then returned to California as Assistant Professor at the Veterans Administration Hospital in Loma Linda, California followed by serving in the US Air Force Medical Corp in Japan and Texas. While in the Air Force he continued clinical research, and then returned to academia by completing a transplant fellowship at the University of Colorado, Denver.  He then served as Assistant Professor and transplant hepatologist at Saint Louis University (SLU), St. Louis, Missouri.  In 2006, he completed a Master of Public Health at SLU.   From 2006, he was Medical Director of Liver Transplantation at the University of North Carolina (UNC), Chapel Hill, and became a Professor of Medicine at UNC before joining the FDA in 2020.  Since 2007, he has been a Co-Principle Investigator in the US Drug-Induced Liver Injury Network (DILIN) and remains Co-Chair of the DILIN’s Causality Committee.  

    Marc Ghany (Moderator)

    Marc G. Ghany, MD, MHSc, FAASLD is an investigator at the Liver Diseases Branch of the National Institute of Diabetes and Digestive and Kidney Diseases, and at Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda. He is member the Physician Consortium for Practice Improvement for Hepatitis C, which is jointly sponsored by the American Medical Association and AASLD and serves on the hepatitis C Guidance panel which is jointly sponsored by the AASLD and Infectious Diseases Society of America. His work has been honored with the Regal Award for Excellence in Gastrointestinal and Liver Disease and with several NIDDK service awards including the Director’s Award. He received his M.B. and B.Ch. from the Royal College of Surgeon’s, Dublin, and Master of Health Sciences in Clinical Research, Duke University. He completed residency at the Hospital of Saint Raphael, New Haven, Connecticut, a fellowship in gastroenterology at Tulane University, New Orleans, and a clinical fellowship at the Liver Diseases Section, NIDDK. Dr. Ghany’s focus is on translational research to improve the care and treatment outcomes of patients with chronic viral hepatitis.

    ​Robert J. Fontana (Moderator)

    Robert J. Fontana, MD, FAASLD, FAGA is a Professor of Medicine and Medical Director of Liver Transplantation at the University of Michigan.  He is a clinical-translational investigator with research interests in viral hepatitis, drug induced liver injury and acute liver failure.  He is co-chair of the Drug Induced Liver Injury Network (DILIN) Steering Committee and an active participant in the Hepatitis B Research Network.   He has also been an active member of the US Acute Liver Failure Study Group since 1998 and is a current Co-PI of this multicenter network.   

  • 2021 Webinar: Practical Approach to Coagulation Management in Cirrhosis

    Contains 2 Component(s) Recorded On: 01/11/2021

    Webinar hosted by the Clinical Practice Special Interest Group on January 11, 2021.

    Coagulation disorders in patients with cirrhosis present challenging situations for clinical providers. This one hour webinar will summarize the knowledge behind coagulation disorders in patients with cirrhosis, including the mixed and thrombosis prone model, limitations in current tests of hemostasis, and the dangers of excessive transfusion. Using practical clinical vignettes, learners will gain understanding of best practice to manage these difficult coagulation situations, including in practice settings where colleagues in hospital medicine and interventional radiology may have different approaches. Vignettes will include an outpatient cirrhotic patient with portal vein thrombosis, an inpatient cirrhotic requiring paracentesis, and an inpatient cirrhotic in the intensive care unit with renal failure and spontaneous mucosal bleeding.

    Nicolas Intagliata

    Nicolas Intagliata, MD is an associate professor of medicine at the University of Virginia. His research is based in hemostasis and liver disease. More specifically, the role of anticoagulation in prevention and treatment of thrombosis in cirrhosis and underlying mechanisms of hemostasis and thrombosis in liver disease. His clinical practice involves caring for patients both in the general hepatology and liver transplantation setting.

    Arul Thomas (Moderator)

    Arul M. Thomas, MD is an assistant professor of medicine at the MedStar Georgetown Transplant Institute at Georgetown University Hospital, in Washington, DC. He has interests in all aspects of clinical transplant hepatology, including autoimmune liver diseases, drug induced liver injury and pediatric to adult transition of care. He serves on the Clinical Practice SIG. He practices also at MedStar Washington Hospital Center, where he fulfills a goal to increase access to advanced liver care in underserved communities in the DC area. At all his clinical sites, he is well-known as an avid educator of trainees.